AU679675B2 - Methods for detecting beta amyloid precursor protein processing enzymes - Google Patents

Methods for detecting beta amyloid precursor protein processing enzymes Download PDF

Info

Publication number
AU679675B2
AU679675B2 AU37110/93A AU3711093A AU679675B2 AU 679675 B2 AU679675 B2 AU 679675B2 AU 37110/93 A AU37110/93 A AU 37110/93A AU 3711093 A AU3711093 A AU 3711093A AU 679675 B2 AU679675 B2 AU 679675B2
Authority
AU
Australia
Prior art keywords
app
cathepsin
amyloid
protease
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU37110/93A
Other languages
English (en)
Other versions
AU3711093A (en
Inventor
Robert N Dreyer
Paul P Tamburini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Publication of AU3711093A publication Critical patent/AU3711093A/en
Assigned to BAYER CORPORATION reassignment BAYER CORPORATION Amend patent request/document other than specification (104) Assignors: MILES INC.
Application granted granted Critical
Publication of AU679675B2 publication Critical patent/AU679675B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8142—Aspartate protease (E.C. 3.4.23) inhibitors, e.g. HIV protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472—Aspartic endopeptidases (3.4.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
AU37110/93A 1992-05-11 1993-04-22 Methods for detecting beta amyloid precursor protein processing enzymes Ceased AU679675B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88091492A 1992-05-11 1992-05-11
US880914 1992-05-11
US99566092A 1992-12-16 1992-12-16
US995660 1992-12-16

Publications (2)

Publication Number Publication Date
AU3711093A AU3711093A (en) 1993-11-18
AU679675B2 true AU679675B2 (en) 1997-07-10

Family

ID=27128594

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37110/93A Ceased AU679675B2 (en) 1992-05-11 1993-04-22 Methods for detecting beta amyloid precursor protein processing enzymes

Country Status (8)

Country Link
EP (1) EP0569777A2 (forum.php)
JP (1) JPH08268911A (forum.php)
KR (1) KR930023469A (forum.php)
AU (1) AU679675B2 (forum.php)
CA (1) CA2095888A1 (forum.php)
IL (1) IL105632A0 (forum.php)
MX (1) MX9302725A (forum.php)
NZ (1) NZ247575A (forum.php)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
NZ264143A (en) * 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
GB9608657D0 (en) * 1996-04-26 1996-07-03 Smithkline Beecham Plc Novel treatment
DE19641180A1 (de) * 1996-09-24 1998-03-26 Schering Ag Verfahren zur Darstellung von APP-Sekretase Modulation und deren Verwendung als Mittel zur Behandlung der Alzheimer'schen Erkrankung
WO1998015828A1 (en) * 1996-10-07 1998-04-16 Scios Inc. Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase
EP1084240A1 (fr) * 1998-06-05 2001-03-21 Aventis Pharma S.A. Polypeptides possedant une activite de type beta-secretase
FR2779444A1 (fr) * 1998-06-05 1999-12-10 Rhone Poulenc Rorer Sa Polypeptides possedant une activite de type beta-secretase et capables de cliver le precurseur naturel du peptide beta-amyloide (app)
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
ES2312348T3 (es) * 1999-06-16 2009-03-01 Boston Biomedical Research Institute Control inmunologico de niveles de beta-amiloide in vivo.
JP2013158281A (ja) * 2012-02-03 2013-08-19 Shionogi & Co Ltd 新規ｂａｃｅ１活性測定方法
CN119044471A (zh) * 2024-08-30 2024-11-29 南京质谱医学科技有限公司 Tau蛋白抗体-CNBr复合物及其制备方法、检测方法、试剂盒和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007068A1 (en) * 1990-10-05 1992-04-30 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
AU5726494A (en) * 1992-12-16 1994-07-04 Bayer Corporation Cathepsin d is an amyloidogenic protease in alzheimer's disease
AU672379B2 (en) * 1992-04-09 1996-10-03 Bayer Corporation Diagnostic assay for Alzheimer's Disease based on the proteolysis of Alzheimer's precursor protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62312A (en) * 1990-03-05 1993-04-28 Cephalon Inc Process for producing chymotrypsin-like proteases and their inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007068A1 (en) * 1990-10-05 1992-04-30 Athena Neurosciences, Inc. Amyloidin protease and uses thereof
AU672379B2 (en) * 1992-04-09 1996-10-03 Bayer Corporation Diagnostic assay for Alzheimer's Disease based on the proteolysis of Alzheimer's precursor protein
AU5726494A (en) * 1992-12-16 1994-07-04 Bayer Corporation Cathepsin d is an amyloidogenic protease in alzheimer's disease

Also Published As

Publication number Publication date
AU3711093A (en) 1993-11-18
JPH08268911A (ja) 1996-10-15
CA2095888A1 (en) 1993-11-12
EP0569777A3 (forum.php) 1993-12-01
IL105632A0 (en) 1993-09-22
KR930023469A (ko) 1993-12-18
EP0569777A2 (en) 1993-11-18
NZ247575A (en) 1996-09-25
MX9302725A (es) 1994-08-31

Similar Documents

Publication Publication Date Title
US5292652A (en) Amyloidin protease and uses thereof
Paborsky et al. Mammalian cell transient expression of tissue factor for the production of antigen
US6221645B1 (en) β-secretase antibody
US5942400A (en) Assays for detecting β-secretase
US5981208A (en) Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein
US7132401B2 (en) Beta-secretase substrates and uses thereof
EP0569777A2 (en) Methods for detecting beta amyloid precursor protein processing enzymes
US9506051B2 (en) Tau protease compositions and methods of use
JPH1121252A (ja) アルツハイマーアミロイドポリペプチドを使用した薬学的組成物および処置方法
WO2000063250A1 (en) Antibodies that recognize app cleaved by caspases and methods of use
Koike et al. Thimet oligopeptidase cleaves the full-length Alzheimer amyloid precursor protein at a β-secretase cleavage site in COS cells
WO1995013084A1 (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
WO1994013319A1 (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
JP4579422B2 (ja) ヒト脳カルボキシペプチダーゼｂ
Herr et al. Purification and microsequencing of the intra-acrosomal protein SP-10. Evidence that SP-10 heterogeneity results from endoproteolytic processes
Nagai et al. No mutations in cystatin C gene in cerebral amyloid angiopathy with cystatin C deposition
Masaki et al. Multicatalytic proteinase is associated with characteristic oval structures in cortical Lewy bodies: an immunocytochemical study with light and electron microscopy
DE69734249T2 (de) Verfahren zur detektion der hk2 polypeptide
NZ272218A (en) Regulation of formation of beta-amyloid with a beta-amyloid precursor protease inhibitor
AU5726494A (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
AU7115094A (en) Cathepsin d is an amyloidogenic protease in alzheimer's disease
JPH02138995A (ja) 新規な蛋白質に対するモノクローナル抗体
HK1026919A1 (en) agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease in humans
ZA200304741B (en) Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide.
HK1026919B (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease in humans